Expression of human endogenous retroviruses (HERVs) in breast cancer: a transcriptomic study
DOI:
https://doi.org/10.2478/AMB-2026-0071Keywords:
HERVs, breast cancer, transcriptomics, RNA-Seq, biomarkers, gene expression, therapy responseAbstract
Abstract. Background: Human endogenous retroviruses (HERVs) are ancient viral elements integrated into the human genome. HERVs, especially HERV-K (HML-2), play a significant role in the onset and advancement of breast cancer. This study examined the
expression of endogenous retroviruses in human breast tissues to reveal potential associations between retroviruses and breast cancer. Materials and methods: RNA-Seq datasets from breast cancer tissues (ductal carcinoma and triple-negative subtypes) and normal breast tissues were retrieved from the NCBI Sequence Read Archive (SRA). Bioinformatics analysis included read mapping against the human genome (hg19) and a custom pseudogenome containing HERV sequences. Normalized expression of HERV-human junctions was calculated, and statistical comparisons were performed using independent samples t-tests and Mann-Whitney tests. Results: Breast cancer tissues exhibited significantly higher normalized coverage of HERV integration sites compared to healthy controls (p = 0.009). Among breast cancer cases, patients who had undergone treatment showed significantly lower HERV expression than untreated patients (p = 0.023). Visualization via IGV confirmed increased read accumulation at HERV loci in cancer samples. Conclusion: HERVs were overexpressed in breast cancer cell lines compared to healthy breast tissue samples, with expression levels influenced by therapeutic interventions. These findings support the potential role of HERVs as biomarkers for breast cancer diagnosis, prognosis, and therapeutic monitoring.
References
Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23.
Giaquinto AN, Sung H, Newman LA, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(5):477–495.
Merrill RM, Gibbons IS. Inequality in female breast cancer relative survival rates between white and black women in the United States. J Racial Ethn Health Disparities. 2024;1–10.
Zhang S, Xiao X, Yi Y, et al. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Ther. 2024;9:149.
Xiong X, Zheng LW, Ding Y, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2024;10:49.
Mao J, Zhang Q, Cong YS. Human endogenous retroviruses in development and disease. Comput Struct Biotechnol J. 2021;19:5978–5986.
Geis FK, Goff SP. Silencing and transcriptional regulation of endogenous retroviruses: an overview. Viruses. 2020;12(8):884.
Lemaître C, Tsang J, Bireau C, et al. A human endogenous retrovirus-derived gene that can contribute to oncogenesis by activating the ERK pathway and inducing migration and invasion. PLoS Pathog. 2017;13(1):e1006451.
Xue B, Sechi LA, Kelvin DJ. Human endogenous retrovirus K (HML-2) in health and disease. Front Microbiol. 2020;11:1690.
Dervan E, Bhattacharyya DD, McAuliffe JD, et al. Ancient adversary - HERV-K (HML-2) in cancer. Front Oncol. 2021;11:658489.
Subramanian RP, Wildschutte JH, Russo C, et al. Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology. 2011;8:90.
Montesion M, Williams ZH, Subramanian RP, et al. Promoter expression of HERV-K (HML-2) provirus-derived sequences is related to LTR sequence variation and polymorphic transcription factor binding sites. Retrovirology. 2018;15:57.
National Center for Biotechnology Information (NCBI). The Sequence Read Archive (SRA) [Internet]. Bethesda (MD): NCBI; [cited 2024]. Available from: https://www.ncbi.nlm.nih.gov/sra
Subramanian I, Verma S, Kumar S, et al. Multi-omics data integration, interpretation, and its application. Bioinform Biol Insights. 2020;14:1177932219899051.
Belshaw R, Pereira V, Katzourakis A, et al. Long-term reinfection of the human genome by endogenous retroviruses. Proc Natl Acad Sci USA. 2004;101(14):4894–4899.
BEDTools. getfasta [Internet]. [cited 2024]. Available from: https://bedtools.readthedocs.io/en/latest/content/tools/getfasta.html
Bartzi D. Human endogenous retroviruses (HERVs) transcriptomics in human breast cancer [Master’s thesis]. Athens: National and Kapodistrian University of Athens; 2021. Available from: https://pergamos.lib.uoa.gr/uoa/dl/frontend/en/browse/2938645#contents
Integrative Genomics Viewer (IGV) [Internet]. [cited 2024]. Available from: https://igv.org/
Costa B, Vale N. Exploring HERV-K (HML-2) influence in cancer and prospects for therapeutic interventions. Int J Mol Sci. 2023;24(19):14631.
Johanning GL, Malouf GG, Zheng X, et al. Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. Sci Rep. 2017;7:41960.
Rivas SR, Valdez MJM, Govindarajan V, et al. The role of HERV-K in cancer stemness. Viruses. 2022;14(9):2019.
Burn A, Roy F, Freeman M, et al. Widespread expression of the ancient HERV-K (HML-2) provirus group in normal human tissues. PLoS Biol. 2022;20(10):e3001826.
Cherkasova EA, Chen L, Childs RW. Mechanistic regulation of HERV activation in tumors and implications for translational research in oncology. Front Cell Infect Microbiol. 2024;14:1358470.
Wei Y, Wei H, Wei Y, et al. Screening and identification of human endogenous retrovirus-K mRNAs for breast cancer through integrative analysis of multiple datasets. Front Oncol. 2022;12:820883.
Wang-Johanning F, Li M, Esteva FJ, et al. Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer. Int J Cancer. 2014;134(3):587–595.
Simula ER, Jasemi S, Cossu D, et al. Human endogenous retroviruses as novel therapeutic targets in neurodegenerative disorders. Vaccines. 2025;13(4):415.
Bannert N, Hofmann H, Block A, et al. HERVs new role in cancer: from accused perpetrators to cheerful protectors. Front Microbiol. 2018;9:178.
Stricker E, Peckham-Gregory EC, Scheurer ME. HERVs and cancer – a comprehensive review of the relationship of human endogenous retroviruses and human cancers. Biomedicines. 2023;11(3):936.
Molla G, Bitew M. Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives. Biomedicines. 2024; 12(12):2750.
Logotheti S, Stiewe T, Georgakilas AG. The role of human endogenous retroviruses in cancer immunotherapy of the post-COVID-19 world. Cancers. 2023;15(21):5321.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 D. Bartzi, A. Philippou, I. Tsatsou, M. Koutsilieris (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
